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ontrast Loaded With
-Acetylcysteine for Coronary
maging During Percutaneous
oronary Intervention
New Concept for Renal and
yocardial Protection During
ercutaneous Coronary Intervention*
im A. Fischell, MD, FACC
alamazoo, Michigan
n this issue of JACC: Cardiovascular Interventions, Meyer et
l. (1) have presented an intriguing concept. They examined
he potential use of N-acetylcysteine (NAC) mixed with
ontrast media to simultaneously provide both cardiac and
enal protective effects in a porcine infarct/reperfusion
odel.
The study is carefully done. The results are provocative
nd suggest a potential benefit, particularly with regard to
enal protection. Although there was evidence of myocardial
protection,” from the NAC injected with the contrast
edia, this benefit carried a potential “cost,” related to
atchy myocardial necrosis, that was associated with serious
entricular arrhythmias after myocardial reperfusion. This
ill be addressed in more detail.
See page 215
NAC has fallen in and out of favor as an agent to reduce
he risk of contrast-induced acute renal failure during
ardiac angiography and/or percutaneous coronary interven-
ion (PCI) (2). Many studies have demonstrated that NAC
either orally or intravenously) has a beneficial, renal pro-
ective effect when administered with appropriate hydration
uring angiography, particularly in patients who are at high
isk of acute renal failure (2–6). A number of published
eta-analyses have further strengthened the argument for
outine use of NAC in patients with pre-existing renal
nsufficiency and/or other major risk factors for acute renal
ailure (e.g., diabetes mellitus) (7–13).
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-l
ions or the American College of Cardiology.
From the Borgess Heart Institute, Kalamazoo, Michigan.Despite this body of evidence suggesting utility of this
gent in reducing the risk of contrast-induced nephropathy,
his treatment is not used routinely at all medical centers. As
uch, it may be important to devise ways to simplify and
ncourage the use of NAC without requiring pre-treatment
efore contrast loading.
The concept of co-administration of NAC admixed with
he contrast agent itself is appealing for the following
easons. 1) It does not require pre-treatment with the agent.
) It provides a significant improvement in ease of use,
articularly when compared with intravenous administra-
ion. 3) Dosing of NAC will be de facto; it will be given
roportional to the contrast load. This may help to ensure
ptimal NAC dosing in each case. This may be important
ecause underdosing of NAC may lead to the failure of this
gent to prevent contrast-induced nephropathy (5).
Although there is an appeal of such an “NAC-enhanced”
ontrast agent for the prevention of contrast nephropathy,
he current study also raises the prospect that this NAC/
ontrast mixture may provide cardioprotective effects during
oronary reperfusion. These potential beneficial cardiac
ffects may be relevant in PCI of ST-segment elevation
yocardial infarction and possibly in other high-risk acute
oronary syndrome cases.
However, as Meyer et al. (1) point out, the patchy
ecrosis pattern seen in the NAC-protected animals, pre-
umably due to this cardioprotective effect of NAC, led to a
orrisome and substantial increase in serious (presumably
e-entrant) ventricular arrhythmias in the treatment group.
his could be a disabling adverse side effect if this were to
e seen in this application in human trials.
Interestingly, the cardioprotective effects of NAC had the
pposite effect in a canine model (14). In the Sochman et al.
tudy (14), there was a significant reduction in life-
hreatening ventricular arrhythmias after reperfusion, using
AC, in dogs. Further investigation of the potential dele-
erious effect of cardioprotection should therefore be con-
ucted before this approach is accepted for use in the setting
f ST-segment elevation myocardial infarction in patients.
The practical aspect of NAC co-administration with
ontrast still needs to be worked out. There could some
ssues related to the “off-label” addition of NAC to the
ontrast bottle. This alteration of a Food and Drug Admin-
stration–approved drug by adding a second agent in the
ardiac catheterization laboratory could be problematic from
ogistical and medical legal standpoints. Ideally, one of the
harmaceutical companies that manufactures contrast
gents may appreciate the potential marketing differentia-
ion of a combined product and could be willing to invest
he resources required to bring such a product to the market,
on-label.” However, there may be drug-to-drug interac-
ions as well as NAC shelf-life issues that could complicate
he development of such a product. This would also, most
ikely, require a new investigational new drug application or
s
c
“
p
N
n
t
f
t
b
b
R
D
M
M
R
1
1
1
1
1
K
f
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 3 , 2 0 0 9
M A R C H 2 0 0 9 : 2 2 2 – 3
Fischell
Editorial Comment
223upplement with the Food and Drug Administration, ne-
essitating a large randomized clinical trial to bring this
dual” agent to the U.S. market.
In summary, the current study by Meyer et al. (1)
rovides a new concept with regard to effective dosing of
AC admixed with contrast to prevent contrast-induced
ephropathy and potentially provides an added cardiopro-
ective effect during high-risk PCI. Carefully designed
easibility trials should be considered. If these initial clinical
rials are positive, a large randomized clinical trial will then
e required before this novel NAC dosing approach could
e considered as a mainstream therapy.
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